Cargando…

Mechanism of Anti-α-Synuclein Immunotherapy

Immunization therapy targeting α-synuclein has emerged as a promising approach for Parkinson’s disease and perhaps for other synucleinopathies. Several antibodies have shown therapeutic effects in mouse models of synucleinopathies and have alleviated the pathological and behavioral phenotypes of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jun Sung, Lee, Seung-Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Movement Disorders Society 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734990/
https://www.ncbi.nlm.nih.gov/pubmed/26828212
http://dx.doi.org/10.14802/jmd.15059
Descripción
Sumario:Immunization therapy targeting α-synuclein has emerged as a promising approach for Parkinson’s disease and perhaps for other synucleinopathies. Several antibodies have shown therapeutic effects in mouse models of synucleinopathies and have alleviated the pathological and behavioral phenotypes of these mice. The mechanisms through which the immunization therapy works were initially puzzling, especially given that α-synuclein is a typical cytosolic protein. Recent studies, however, suggested that extracellular α-synuclein is an important pathogenic entity, and hence, a target for immunotherapy. Here, we review the literature describing immunization therapy for synucleinopathies in mouse models and provide current thoughts on the potential mechanisms underlying the therapeutic effects of α-synuclein immunotherapy.